As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...

ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...

CHENNAI: A division bench of the Delhi High Court on Monday allowed Indian drugmaker Zydus Lifesciences to sell and market ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...

Correspondence to Dr Nicholas Makins, Department of Philosophy, King's College London, London, WC2R 2LS, UK; ndmakins{at}gmail.com A lively topic of debate in decision theory over recent years ...